PHEN Clinical Trials Rally  Raising the awareness and knowledge about prostate cancer clinical trials to increase African American participation.

PHEN Clinical Trials Rally The number of African American men participating in prostate cancer clinical trials is rarely large enough to determine how well new treatments work for the population at highest risk for prostate cancer. There are certain genetic differences in prostate cancer for black and white men and because of these differences only clinical trials participation can identify, for certain, how black men respond to specific treatments.  

Clinical Trials Past and Present There is a dark history of African Americans and medical experimentation. The Tuskegee experiment is but one of many medical atrocities committed against African Americans Clinical trials safeguards are now in place to prevent these type of experiments. Today’s atrocity is that African Americans are not included in clinical trials leaving a void of scientific evidence as to which treatments works best for us.

Why Should African American Patients Participate in Clinical Trials? Clinical trials are treatment options.   Clinical trials provide access to new innovative treatments (At No Cost) that are not available to patients outside the trial. Patients receive expert medical care to provide close monitoring of their condition. If the treatment being studied is more effective than the standard treatment you may be among the first to benefit. Participation will help doctors develop new treatments and determine how well they work for black men today and for future generations.

Clinical Trial Summaries Summaries of A select group of phase 3 prostate cancer clinical trials to provide patients with a snapshot overview of the purpose, potential benefits and risks of each trial.

EMBARK Clinical Trial This trial is for patients with a rising PSA after being treated with surgery, radiation or both. Trial summary description: Patients are randomly (by chance) assigned to either a group to receive Xtandi plus Lupron or to a group which will receive only Xtandi or Lupron plus placebo. Lupron is the standard of care for patients with high-risk non-metastatic prostate cancer. Possible patient benefits: Increase time before prostate cancer spreads (progresses) and metastasizes. Prolong life.   Possible patient risks: That Xtandi alone or in combination with Lupron does not work as well as Lupron alone. Organization conducting this trial: Medivation Inc. (A Pfizer company)

ENACT Clinical Trial This trial is for patients considering active surveillance or currently undergoing active surveillance. Trial description: Patients are randomly (by chance) assigned to a group to receive the drug Xtandi or to a group that will undergo active surveillance. Neither the researchers nor the patient can choose who is assigned to which group.   Possible patient benefits: Preventing or slowing the progression of prostate cancer. All patients will be closely monitored to detect any possible progression of their cancer. Possible patient risks: That Xtandi does not work any better than undergoing active surveillance. Organization conducting this trial: Astellas Pharma Inc.

ATLAS Clinical Trial This trial is for patients diagnosed with high-risk, localized or locally advanced prostate cancer as determined by a high PSA and/or Gleason Score and cancer stage.   Trial description: Patients are randomly assigned to a group whose treatment is a combination of the experimental drug ARN 509 plus hormone therapy plus radiation, or to a group whose treatment is FDA approved hormone therapy plus radiation. Possible patient benefits: Reduced potential for spread of prostate cancer following primary radiation treatment. All patients receive treatment beyond their primary radiation treatment. Possible patient risks: That the combination of ARN 509 plus hormone therapy plus radiation does not work any better than hormone therapy plus radiation alone.

TITAN Clinical Trial This trial is for patients with prostate cancer that has spread to their bones but hormone (androgen deprivation) therapy still keeps the PSA low. This is called Metastatic Hormone-sensitive Prostate Cancer (MHSPC).   Trial description: Patients are randomly (by chance) assigned to a group whose treatment is a combination of the experimental drug ARN-509 and FDA approved hormone therapy, or to a group whose treatment is a placebo plus FDA approved hormone therapy. Possible patient benefits: Slowing the progression of prostate cancer and prolonging life. Delayed onset in pain progression, chronic use of pain relievers, delayed bone problems and chemotherapy use. Possible patient risks: That the combination of hormone therapy and ARN-509 does not work any better than the hormone therapy alone. Organization conducting this trial: Janssen Oncology (Aragon Pharmaceuticals)   

For More Information Visit: www.PHENtrials.com Summary   Patients should talk with their doctors and clinical trials experts about the Benefits and Risks of clinical trial participation Visit PHENtrials.com for information about clinical trials and to find prostate cancer clinical trials PHEN invites prostate cancer patients and their loved ones to join the PHEN Network to receive up – to – date clinical trials information and to support the fight against prostate cancer. Thank You! For More Information Visit: www.PHENtrials.com